Preoperative embolization in patients with metastatic spinal cord compression: mandatory or optional? by unknown
RESEARCH Open Access
Preoperative embolization in patients with
metastatic spinal cord compression:
mandatory or optional?
Chul Gie Hong1, Jae Hwan Cho2*, Dae Chul Suh3, Chang Ju Hwang2, Dong-Ho Lee2 and Choon Sung Lee2
Abstract
Background: The contribution of preoperative embolization in reducing intraoperative blood loss and its clinical
importance are unclear. So, we aimed to compare the perioperative clinical outcomes based on whether
preoperative embolization was performed and assess the role and safety of preoperative embolization in metastatic
spinal cord compression (MSCC) patients.
Methods: We enrolled 52 patients (men, 37; women, 15) who underwent palliative decompression for MSCC.
Demographic data, neurologic status, surgery-related data (operation time, estimated blood loss, and transfusion),
complications, and survival time were recorded. Patients were categorized based on whether they received preoperative
embolization: groups E (embolization) (n = 18) and NE (non-embolization) (n = 34) and the clinical parameters were
compared. Subgroup analysis was performed specifically for cases of hypervascular tumors (23/52, 44%).
Results: The transfusion degree was greater in the NE group (4.6 pints) than in the E group (2.5 pints, P = 0.025); the
other parameters did not differ between the groups. However, massive bleeding (>2000 mL) was more frequent in the
NE group (10/34) than in the E group (0/18, P = 0.010). Subgroup analysis indicated that intraoperative blood loss was
greater in the NE group (1988 mL) than in the E group (1095 mL, P = 0.042) in hypervascular tumor patients. Although
massive bleeding was more frequent among hypervascular tumor patients, 3 patients with non-hypervascularized
tumors also exhibited massive bleeding (P = 0.087).
Conclusions: Intraoperative blood loss and perioperative transfusion can be reduced by preoperative embolization in
MSCC patients. Neurologic recovery, operation time, and complications did not differ according to the application of
embolization. As preoperative embolization is relatively safe and effective for controlling intraoperative bleeding without
any neurologic deterioration, it is highly recommended for hypervascular tumors. Moreover, it may also be effective for
non-hypervascular tumors as massive bleeding may be noted in some cases.
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Background
Metastatic spinal cord compression (MSCC) is a critical
problem for patients with spinal metastasis. MSCC is
reportedly observed in 5–10% of cases with advanced can-
cer [1]. It is important to diagnose MSCC in the early
period to avoid neurologic deficits. However, studies have
found that 48% of patients are unable to walk at the time
of diagnosis [1]. The treatment of MSCC depends on the
primary tumor, neurologic status, progression of limb
weakness, tumor burden, performance status, life expect-
ancy, and possibility of other therapeutic options such as
radiotherapy [2–6]. No definite guidelines for MSCC
treatment are available. In general, palliative decom-
pressive surgery could be considered in cases where pro-
gressive neurologic deficit is observed, physical activity is
relatively good, and multiple metastasis has been proven.
Moreover, the need for surgical treatment is increasing, as
longer associated survival is expected and the surgical
technique has been well studied [7].* Correspondence: doctork78@hanmail.net2Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan
College of Medicine, 388-1, PungNap-2-dong, SongPa-gu, Seoul, Korea
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Palliative decompression surgery for MSCC is associ-
ated with problems such as potential massive bleeding
and postoperative complications [8]. Several authors
have suggested that preoperative embolization could re-
duce intraoperative blood loss in cases of hypervascular
tumors and could thus simplify the operative procedures
[9–11]. However, some studies have indicated that the
blood loss does not differ when embolization is per-
formed in cases of non-hypervascular tumors [12, 13].
Moreover, the risk of cord infarction or progression of
the neurologic status as a result of operative delay are con-
cerns related to the preoperative embolization procedures.
Hence, the clinical benefits and risks of preoperative
embolization need to be carefully evaluated, particularly in
non-hypervascular tumors. To our knowledge, no definitive
conclusion or guideline has been established with regard to
the clinical importance of preoperative embolization.
In the present study, we aimed to compare the peri-
operative clinical outcomes based on whether preoperative
embolization is performed in patients with MSCC and to
assess the role and safety of preoperative embolization.
Methods
Patients and clinical parameters
We enrolled a total of 52 consecutive patients (37 men
and 15 women) who underwent palliative decompression
for MSCC from March 2012 to December 2014 at a
single center. Demographic data, neurologic status,
surgery-related data (operation time, estimated blood
loss, and transfusion), complications, and survival time
were recorded from the electronic medical records at
our institution. The neurologic status was assessed based
on the motor strength of the lower extremity: grade 0,
no muscle contraction; grade 1, minimal muscle con-
traction; grade 2, active movement under gravity-free
conditions; grade 3, active movement under gravity;
grade 4, active movement under limited resistance; and
grade 5, no weakness. If the values differed between the
right and left lower extremities, the average values were
adopted for analysis. The performance status was
assessed using the Karnofsky performance status scale.
The degree of tumor involvement was assessed by Bilsky
scale [14]. The degree of instability was evaluated by
Spinal Instability Neoplastic Score (SINS) [15]. Oper-
ation time was measured from skin incision to closure.
Intraoperative blood loss was estimated based on the dif-
ference in the volume of suction drainage and irrigation
fluid. The degree of transfusion was determined accord-
ing to the use of packed red blood cells (RBC). The
complications included surgical (hematoma, infection, or
wound dehiscence) and medical (pneumonia, cardiac
problem, or sudden death) problems. Although angiog-
raphy was performed to assess hypervascularity as far as
possible, we did not perform angiography because of the
following reasons in many cases: (1) rapid progression of
neurologic deficit, (2) lack of support such as absence of
interventional radiologists, and (3) surgeon’s judgment
after consideration of risk and benefit of embolization.
Patients were categorized based on whether they under-
went preoperative embolization: group E (embolization)
and group NE (non-embolization). The clinical parame-
ters were compared between the two groups. Subgroup
analysis was performed specifically in the cases of hyper-
vascular tumors (hepatocellular carcinoma, renal cell
carcinoma, and thyroid cancer).
Embolization procedure
Embolization was performed by radiologists with the
patient under local anesthesia. A 4-F or 5-F catheter was
used to perform diagnostic angiography. Angiography of
the vertebral arteries, segmental arteries, and feeding
branches supplying the tumors was performed. There-
after, embolization with polyvinyl alcohol (PVA) particles
and/or gelatin sponge (Gelfoam) was performed. If the
branches supplying the tumors could be approached
directly, then the particles were infused by introducing a
microcatheter. If these branches could not be approached,
then the normal branches distal to the feeder were pro-
tected by Gelfoam or coil prior to the infusion of particles.
If the feeding vessels were too small to be identified,
embolization was not performed. Repeat angiography was
performed immediately to confirm residual tumor staining
after embolization. An example of the embolization
procedure is shown in Fig. 1.
Surgical procedure
Surgery was performed within 48 h after embolization.
Instrumentation was performed using pedicle screws
and rods across two levels, above and below the lesion.
Thereafter, posterior decompression with total laminec-
tomy was performed. Additional tumor resection was
performed in certain cases. However, corpectomy of the
vertebral body via the transpedicular approach or anter-
ior approach was not performed. Bone grafting was also
not routinely performed because of the short-term life
expectancy of the patients. Two suction drains were
placed after careful hemostasis. An example of a surgical
case in a patient with MSCC is shown in Fig. 2.
Statistical analyses
The demographic and operation-related parameters were
compared between the two groups by using the inde-
pendent t test, Mann Whitney U test, chi-square test, or
Fisher’s exact test. Survival analysis was conducted with
the Kaplan-Meier method and log-rank test. All statistical
analyses were performed using the Statistical Package for
the Social Sciences version 21.0 (SPSS Inc., Chicago, IL); P
values <0.05 were considered to be statistically significant.
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Fig. 1 Angiography and embolization procedure in a 52-year old HCC patient with MSCC at T6. a Angiogram at the left 6th intercostal artery was
obtained (left), hypervascular staining was observed (middle), and embolization was successful (right). b The same procedure was repeated at the
right 6th intercostal artery. Hepatocellular carcinoma (HCC), metastatic spinal cord compression (MSCC)
Fig. 2 A 54-year old man with HCC who developed MSCC. a Preoperative T2-weighted sagittal MR image showing cord compression at T7. b Preoperative
T1-weighted enhanced MR image (arrows indicate cord compression by the tumor mass). c Postoperative radiographs. d T2-weighted sagittal MR image
6 months postoperatively showing another occurrence of cord compression at T2, with maintenance of the decompression at T7. e T1-weighted enhanced
MR image at T2 (arrows indicate tumor mass). Hepatocellular carcinoma (HCC), metastatic spinal cord compression (MSCC)
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Results
Demographic data
The mean patient age at the time of operation was 59.7 ±
12.3 years. The most common origin of the cancers was
hepatocellular carcinoma (HCC) (n = 12, 23.1%), followed
by renal cell carcinoma (RCC) (n = 10, 19.2%) and lung
cancer (n = 9, 17.3%). The most commonly involved sites
were T6 (n = 9) and T7 (n = 10), followed by T3 (n = 8)
and T4 (n = 7). The estimated blood loss was 1.22 ±
0.95 L, and the mean degree of transfusion was 3.9 ±
4.2 pints. The operation time was 198 ± 54 min.
Preoperative embolization
Of the 52 study patients, 24 (46.2%) underwent pre-
operative angiography. However, 6 patients did not
undergo embolization due to the presence of small arter-
ies (n = 3), risk of cord infarction (n = 2), and difficulty
with accessibility due to the presence of markedly tortu-
ous vessels (n = 1). Thus, 18 patients (34.6%) underwent
preoperative embolization. The involved vessels were
segmental arteries or intercostal arteries that supply the
tumors. No procedure-related complications were ob-
served in 18 cases. Complete or near-complete (>80%)
embolization was possible in 13 cases (72.2%). Partial
embolization was performed in the other 5 cases due to
the risk of cord ischemia or an inaccessible location. The
time period between embolization and the surgical pro-
cedure was 16.4±9.1 h.
Comparisons of demographic and operation-related
parameters
Eighteen and 34 patients were assigned to groups E and
NE, respectively. The preoperative demographic data did
not significantly differ between the two groups (Table 1).
However, the neurologic status in the NE group was in-
ferior to that in the E group (2.7 vs 3.6), although the
difference was not significant (P = 0.067). The postopera-
tive neurologic status was also different between the two
groups (2.9 vs 3.8, P = 0.042); however, the degree of
neurologic improvement did not significantly differ
(P = 0.519). Moreover, the degree of transfusion was
greater in the NE group (4.6 pints) than in the E
group (2.5 pints, P = 0.025). Blood loss, operation
time, and complications did not differ between the
two groups. However, massive bleeding (>2000 mL)
was more frequent in the NE group (10/34) than in the E
group (0/18, P = 0.010). A comparison of the intraopera-
tive and perioperative parameters is described in Table 2.
Of the 52 patients, 23 (44%) exhibited hypervascular tu-
mors. A greater amount of intraoperative blood loss was
observed in the cases with hypervascular tumors
(1600 mL vs 916 mL, P = 0.015). Although massive bleed-
ing was more frequently noted in cases with hypervascular
tumors, 3 patients with non-hypervascularized tumors
(prostate cancer, germ cell tumor, and breast cancer) also
showed massive bleeding (P = 0.087). The comparisons
between hypervascular and non-hypervascular tumors are
described in Table 3.
Subgroup analysis indicated that intraoperative blood
loss was greater in the NE group (1988 mL) than in the
E group (1095 mL, P = 0.042) in cases of hypervascular
tumors. Although 53.8% of patients in the NE group
exhibited massive bleeding, none of the patients in the E
group exhibited massive bleeding (P = 0.007). The results
of subgroup analysis for cases of hypervascular tumors
are summarized in Table 4. Subgroup analysis between
HCC (12 cases) and RCC (10 cases) showed no differ-
ences in demographic data, operation-related data, and
clinical outcomes. In addition, no differences according
to involved levels (T1–5 vs T6–12) could be found.
Perioperative complications and survival analysis
The most common complications of palliative decom-
pression for MSCC were pulmonary problems (7/52,
13.5%) and wound problems (6/52, 11.5%) including
seroma formation. Four patients (7.7%) exhibited wound
dehiscence, and repeated debridement and advancement
flap operations were performed by plastic surgeons.
Table 1 Demographic data of two groups classified by preoperative embolization
Group NE (n = 34) Group E (n = 18) P value
Age (year) 60.7 ± 12.6 57.7 ± 11.6 0.396
Sex M:F = 21:13 M:F = 16:2 0.055
Hypervascular tumor 13/34 (38.2%) 10/18 (55.6%) 0.232
Preop. RTx 11/34 (32.4%) 7/18 (38.9%) 0.637
Bilsky scale (Gr1:Gr2:Gr3) 6:11:17 2:7:9 0.790
Preop. neurologic status (Gr) 2.7 ± 1.7 3.6 ± 1.4 0.058
SINS 8.2 ± 2.1 7.2 ± 1.8 0.070
Site (≥T5:<T5) 14:20 7:11 0.873
Karnofsky performance 64.1 ± 14.0 71.7 ± 12.0 0.058
Means and standard variation are shown for continuous variables, and the number of cases is shown for categorical variables
NE non-embolization, E embolization, Preop preoperative, RTx radiotherapy, SINS Spinal Instability Neoplastic Score, Gr grade
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Another 2 patients showed postoperative hematoma; 1
patient was successfully treated via hematoma evacu-
ation, whereas the other showed permanent neurologic
deficits following hematoma evacuation. In that case,
massive bleeding was observed, and blood loss persisted
after surgery due to the reduced coagulative ability. After
hematoma evacuation, angiography and embolization
were performed to control the bleeding. The periopera-
tive complications in the overall cohort are summarized
in Table 5.
The mean estimated survival time was 14.8 ± 5.9 months,
and the median survival time was 8.0 ± 2.6 months. The
Kaplan-Meier survival curve is illustrated in Fig. 3.
Survival did not significantly differ between the NE group
and E group (P = 0.321).
Discussion
Patients with MSCC are frequently encountered in the
clinical setting. Moreover, as most metastatic spinal tu-
mors are hypervascular in nature, it is essential to focus
on decreasing the intraoperative blood loss [16]. Several
reports have described the usefulness of preoperative
embolization in reducing intraoperative blood loss in
spinal tumors [10, 17, 18]. In particular, embolization
has been reported to be effective for reducing blood loss
in hypervascular tumors such as RCC [9, 12, 18]. How-
ever, several reports have suggested that the procedure
does not decrease blood loss, and instead, care must be
taken to avoid cord ischemia [19]. Furthermore, it was
reported that there was no difference in blood loss
between the use of local hemostatic agents and pre-
operative embolization [20]. Thus, no definitive guide-
lines regarding preoperative embolization have been
established for the treatment of MSCC patients.
To determine the superiority of the routine clinical
use of preoperative embolization, the assessment of the
risk of the procedure is critical. In our present study, none
of the patients showed procedure-related complications,
including neurologic deficits. However, embolization was
not performed in 2 patients because of the risk of cord in-
farction due to occlusion of the anterior spinal arteries. In
fact, cord ischemia may be the most critical complication
Table 2 Intraoperative and perioperative parameters between two groups
Group NE (n = 34) Group E (n = 18) P value
Postop. neurologic status (Gr) 2.9 ± 1.8 3.8 ± 1.3 0.066
Postop. neurologic improvement 12/34 (35.3%) 8/18 (44.4%) 0.519
Op. time (min) 197.0 ± 60.1 201.2 ± 42.1 0.790
Levels of laminectomy 1.3 ± 0.5 1.2 ± 0.5 0.604
EBL (L) 1.37 ± 1.11 0.99 ± 0.47 0.098
Transfusion (pint) 4.6 ± 4.9 2.5 ± 1.5 0.025
Massive bleeding 10/34 (29.4%) 0/18 (0%) 0.010
Complication 9/34 (26.5%) 5/18 (27.8%) 0.919
Massive bleeding is defined by intraoperative bleeding more than 2 L
NE non-embolization, E embolization, Postop. postoperative, Op. operation, EBL estimated blood loss, Gr grade
Table 3 Comparisons between hypervascular and non-hypervascular tumor
Hypervascular (n = 23) Non-hypervascular (n = 29) P value
Age 55.8 ± 10.3 62.7 ± 13.0 0.043
Sex M:F = 19:4 M:F = 18:11 0.132
Preop. neurologic status (Gr) 3.1 ± 1.7 2.9 ± 1.6 0.571
Postop. neurologic status (Gr) 3.2 ± 1.7 3.3 ± 1.6 0.857
Bilsky scale (Gr1:Gr2:Gr3) 5:6:12 3:12:14 0.370
SINS 7.7 ± 1.9 8.0 ± 2.1 0.505
Karnofsky performance 67.8 ± 14.8 65.9 ± 13.0 0.612
Number of laminectomy 1.2 ± 0.5 1.3 ± 0.5 0.553
Op. time (min) 204.6 ± 61.7 193.4 ± 47.4 0.466
EBL (L) 1.60 ± 1.14 0.92 ± 0.64 0.015
Transfusion (pint) 4.5 ± 4.4 3.4 ± 3.9 0.366
Massive bleeding 7/23 (30.4%) 3/29 (10.3%) 0.087
Complication 4/23 (17.4%) 10/29 (34.5%) 0.217
Gr grade, EBL estimated blood loss, SINS Spinal Instability Neoplastic Score
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of this procedure. Based on an animal study, contiguous
ligation of three segmental vessels bilaterally did not lead
to any neurologic compromise [21]. However, the ligation
of >4 levels produced ischemic cord dysfunction in a dog
model [22]. Therefore, we performed embolization up to
two levels bilaterally, and up to three levels unilaterally,
which we considered to be safe. The safety of embolization
has also been reported by several authors [10, 23, 24].
However, most of these authors also indicated the risk of
cord ischemia.
The factors associated with the effectiveness of pre-
operative embolization remain unclear. Although it
could be reasonable that less blood loss was found in
cases of complete occlusion [11, 25], no difference in
blood loss was observed according to the completeness
of the occlusion [17, 23]. In addition, the time interval
may be another important parameter. Some authors pro-
posed that preoperative embolization was effective when
the time from the procedure to the index surgery was <24 h
[25]. In contrast, other authors did not find any correlation
between the time interval and intraoperative blood loss
[17]. Furthermore, as surgical timing is critical for mitigat-
ing a decline in neurologic function, a delay in the operation
due to preoperative embolization may be a problem.
However, in the present study, we found that none
of the patients showed a progression of neurologic
deficits, even though the average time interval be-
tween the procedure and the index operation was
16 h. Nevertheless, this finding was not conclusive,
as patients with more severe neurologic deficit
tended to undergo surgery more promptly without
embolization (P = 0.067).
The abovementioned controversial results could be
attributed to the retrospective nature of those studies. A
randomized controlled trial showed no difference in blood
loss and transfusion based on whether preoperative
Table 4 Subgroup analysis for hypervascular tumors (HCC, RCC, and thyroid ca.)
Group NE (n = 13) Group E (n = 10) P value
Preop. neurologic status (Gr) 2.4 ± 1.7 4.0 ± 1.4 0.023
Postop. neurologic status (Gr) 2.4 ± 1.8 4.2 ± 1.0 0.006
Postop. neurologic improvement 4/13 (30.8%) 4/10 (40.0%) 0.685
Op. time (min) 208.3 ± 78.8 199.8 ± 31.3 0.790
EBL (L) 1.99 ± 1.37 1.10 ± 0.40 0.042
Transfusion (pint) 5.6 ± 5.6 3.0 ± 1.5 0.156
Massive bleeding 7/13 (53.8%) 0/10 (0%) 0.007
Complication 2/13 (15.4%) 2/10 (20.0%) 1.000
Gr grade, EBL estimated blood loss
Table 5 Summary of perioperative complications
Case Origin Group EBL Complications Progression
1 Lung cancer NE 1500 Respiratory failure Death in 1 week
2 Lymphoma NE 1500 Wound dehiscence Advancement flap by plastic surgeon
9 Breast cancer NE 2000 Hematoma Neurologic recovery after hematoma evacuation
10 RCC NE 3000 Pneumonia Recovery after medical treatment
14 Plasmacytoma NE 1000 Pulmonary thromboembolism Recovery after insertion of IVC filter, anticoagulation
therapy
21 RCC E 1600 Pneumothorax Tracheostomy status. Expire in 3 months due to
respiratory failure
25 Rectal cancer E 300 Wound dehiscence in 1 month Advancement flap by plastic surgeon
35 RCC E 800 Wound dehiscence Advancement flap by plastic surgeon
38 Esophageal cancer NE 400 Pneumonia Recovery after medical treatment
40 Breast cancer NE 400 Dural tear, seroma Observation
43 Lung cancer E 600 Wound infection in 1 month Debridement (+). Death in 6 weeks due to respiratory
failure
50 Klatskin tumor E 400 Dural tear, wound dehiscence Advancement flap by plastic surgeon
51 myeloma NE 200 Atelectasis Recovery after chest tube insertion
52 HCC NE 4000 Neurologic deficit by hematoma, respiratory failure Persistent neurologic deficit after hematoma
evacuation
EBL estimated blood loss, RCC renal cell carcinoma, HCC hepatocellular carcinoma, E embolization, NE non-embolization, PS plastic surgery
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embolization was performed, although the patients
with preoperative embolization did exhibit a reduction
in surgical time [13]. However, that study had certain
limitations, such as the heterogeneity of the popula-
tion in terms of differing vascularity and a relatively
small sample size. An assessment of the hypervascu-
larity of the tumors would be critical for predicting
intraoperative bleeding. However, no definite tools for
such an assessment have been developed thus far. In
particular, MRI characteristics are not known to be
reliable for determining vascularity [26]. Therefore,
we believe that routine angiography could be better
for identifying tumor vascularity, as it is not associ-
ated with any adverse effects such as neurologic
deterioration.
The present study had certain limitations of note.
First, the number of patients who underwent pre-
operative embolization procedures was relatively
small. Hence, the effect of complete or partial occlu-
sion of feeder arteries could not be assessed. Second,
some of the tumors classified as non-hypervascular
tumors might have had some extent of hypervascu-
larity. Previous reports have stated that breast cancer
or prostate cancer occasionally exhibits hypervascu-
lar features [27]. Third, although surgery was
performed by a single surgeon, angiography and
embolization were conducted by multiple radiolo-
gists. Hence, the completeness of the embolization
could be influenced by the technique or experience
of the radiologist. Fourth, selection bias should be
considered, as patients with greater neurological
deterioration tended to be selected for emergent
operation without embolization.
Despite these limitations, however, this study showed
that preoperative embolization is relatively safe and ef-
fective for reducing intraoperative blood loss in surgery
for MSCC. Furthermore, preoperative embolization is
critical for minimizing the probability of massive bleeding
in non-hypervascular as well as hypervascular tumors.
Conclusions
In conclusion, intraoperative blood loss and periopera-
tive transfusion can be reduced by using preoperative
embolization in patients with MSCC. The neurologic
recovery and complications do not differ based on
whether embolization was performed. As preoperative
embolization is relatively safe and effective for control-
ling intraoperative bleeding without any neurologic
deterioration, it is highly recommended for hypervascu-
lar tumors. Furthermore, preoperative embolization can
serve as a good option for non-hypervascular tumors, as
massive bleeding was also found in certain cases.
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